Invesco Dorsey Wright Healthcare Momentum ETF PTH
Set alert
59.78 USD -1.50 -2.45%
At close · Oct 30
59.78 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
58.98 Day range 60.76
46.40 52-week range 64.07
- YTD
- +20.28%
- 1 year
- +24.36%
- Open
- 60.76
- Prev close
- 61.28
- Mkt cap
- 142.85M
- Vol
- 18.35K
- Avg vol
- 40.09K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 58.98
- High
- 60.76
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 44.93
- 200-d avg
- 44.07
1M chart
Signals (8)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 9.15
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 44.93
- 200-day average
- 44.07
About Invesco Dorsey Wright Healthcare Momentum ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of at least 30 securities of companies in the healthcare sector that have powerful relative strength or "momentum" characteristics.
News
- TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
- Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
- Should You Invest in the Invesco Dorsey Wright Healthcare Momentum ETF (PTH)?
- Micot Pharma Reports Positive Operating Cash Flow and Advances Late-Stage Pipeline in 1H 2026
- Moderna Advances Ebola Vaccine Into Human Testing
- Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
- Should You Invest in the Invesco Dorsey Wright Healthcare Momentum ETF (PTH)?
- Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
- Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
- 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
Your note
Sign in to keep a note on PTH — it syncs with the Stock Master app.